|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Few heterozygous mutations in IGF1R leading to IGF-I resistance and intrauterine and postnatal growth retardation have been described to date.
|
20103656 |
2010 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the expression and regulation of IGFBPs in tissues from patients with mono-allelic deletion of the IGF-I receptor gene may lead to IGF sequestration and contribute to IGF-I resistance and growth retardation.
|
15476454 |
2004 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In vivo and in vitro IGF-I resistance in Arg59Ter subjects and fibroblasts indicates a human IGF1R gene dosage effect involving not only the IGF-IR, but also IGF-IR/IR hybrids.
|
16569742 |
2006 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A unique G310D variant in IGF1R, which occurs in 6% American Indians, may impair IGF1R signalling pathways, thereby increasing the risk of T2D.
|
29470850 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found that activation of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway contributes to afatinib resistance in NSCLC cells harboring the T790M mutation.
|
26052929 |
2016 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In comparison, the six different IGF1R mutations revealed to date exhibit some variance in their clinical features as well, probably because different parts of the downstream IGF1R signalling cascade were affected.
|
19955558 |
2010 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Since insulin-like growth factor 1 receptor (IGF1R) signaling and phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signaling have been shown to play a pivotal role in regulating osteogenesis, we hypothesized that the osteogenic activity of calycosin is mediated by these signaling pathways.
|
30632644 |
2019 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Grb10 (growth factor receptor-bound protein 10)-interacting GYF protein 1 (GIGYF1) can modulate insulin-like growth factor 1 receptor (IGF1R) signaling pathway, which plays an important role in regulating diabetes-associated cognitive impairment, by linking to Grb10 adapter.
|
30376373 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Aberrant insulin-like growth factor I receptor (IGF1R) signaling pathway serves as a well-established target for cancer drug therapy.
|
30195750 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), because IGF1R signaling is downregulated by multiple AKT and mTOR feedback mechanisms.
|
25172964 |
2014 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
It has been shown that G-protein-coupled receptor kinase 2 (GRK2) negatively regulates the insulin-like growth factor 1 receptor (IGF1R) signalling pathway in hepatocellular carcinoma (HCC).
|
28202495 |
2017 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
On the other hand, ezrin phosphorylation at Thr-567 by insulin-like growth factor 1 receptor (IGF1R) signaling leads to cAMP-dependent PKA activation and enhances cell survival.
|
29599290 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
We first generated the adenovirus that simultaneously expresses three human or mouse siRNAs targeting IGF1R (AdRIGF1R-OK). qRT-PCR and immunofluorescence staining revealed that IGF1R expression was significantly decreased in the melanoma cells that were infected with AdRIGF1R-OK. Bioluminescence imaging showed that the size of the tumor formed by the xenografts infected with AdRIGF1R-OK was significantly smaller than that of the controls.
|
30161025 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
ER+ ILC cell lines and xenograft tumor explant cultures were used to evaluate efficacy to IGF1R pathway inhibition in combination with endocrine therapy.<b>Results:</b> Diminished functional E-cadherin increased both activation of IGF1R signaling and efficacy to anti-IGF1R/InsR therapies.
|
29941485 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibition of the IGF1R signaling pathway by humanized recombinant IGF1R monoclonal antibody MK-0646 in athymic mouse subcutaneous xenografts resulted in inhibition of p-ezrin T567 indicating ezrin signaling is downstream of the IGF1R signaling pathway.
|
24462708 |
2014 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Lung adenocarcinoma cells harboring KRAS mutations have been shown previously to be selectively sensitive to inhibition of mitogen-activated protein kinase kinase (MEK) and insulin-like growth factor 1 receptor (IGF1R) signaling.
|
31534020 |
2019 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor-1 receptor (IGF1R) signalling has been previously implicated in trastuzumab resistance.
|
20647220 |
2011 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Sublines established from stroma-treated FR-cells (C-FR cells) and D-cells (C-D cells) show permanently high expression of integrin β1 as well as Bcl-3 and P-STAT3 (C-FR) or IGF1R (C-D).
|
29774124 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results were in contrast to those in the seminoma cell line TCAM2 that lacked IGF1R signalling via AKT and was one of the two cell lines least sensitive to the IGF1R inhibitor.
|
29160922 |
2018 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
IGF-I resistance is seen in heterozygous defects of the IGF1R.
|
21396571 |
2011 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
IGF-I resistance is seen in heterozygous defects of IGF1R.
|
22423513 |
2011 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
Seminal studies using post-mortem brains of patients with Alzheimer's disease evidenced aberrant insulin-like growth factor 1 receptor (IGF1R) signalling.
|
28595357 |
2017 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
To examine genetically the involvement of Irs1 and Irs2 in Igf1r signaling, we generated double mutant mice lacking Igf1r specifically in pancreatic β cells in an Irs1- or Irs2-null background.
|
20947509 |
2010 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
We show here that pharmacologic inhibition or genetic deletion of insulin-like growth factor 1 receptor (IGF1R) blocks the growth and viability of T-ALL cells, whereas moderate diminution of IGF1R signaling compromises leukemia-initiating cell (LIC) activity as defined by transplantability in syngeneic/congenic secondary recipients.
|
21807868 |
2011 |
|
Resistance to Insulin-Like Growth Factor I
|
0.700 |
Biomarker
|
disease |
BEFREE |
The reported retention of the nascent IGF1R in the endoplasmic reticulum presents a novel mechanism of IGF-I resistance.
|
20357178 |
2010 |